Pascal Dô

1.7k total citations
28 papers, 617 citations indexed

About

Pascal Dô is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Pascal Dô has authored 28 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Pascal Dô's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Pascal Dô is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Pascal Dô collaborates with scholars based in France, Luxembourg and Spain. Pascal Dô's co-authors include Nicolas Aide, Charline Lasnon, Cédric Desmonts, C. Chouaïd, Radj Gervais, Catherine Dubos‐Arvis, Elske Quak, A. Vergnenègre, J.B. Auliac and J. Madelaine and has published in prestigious journals such as Journal of Clinical Oncology, European Respiratory Journal and European Journal of Cancer.

In The Last Decade

Pascal Dô

27 papers receiving 607 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pascal Dô France	14	397	279	194	125	70	28	617
Carlo Furlan Italy	13	252 0.6×	180 0.6×	134 0.7×	113 0.9×	20 0.3×	29	515
Ryan D. Stephenson United States	9	370 0.9×	281 1.0×	185 1.0×	98 0.8×	12 0.2×	18	539
Praveen Sridhar United States	13	135 0.3×	149 0.5×	59 0.3×	81 0.6×	45 0.6×	29	425
Gilles Quéré France	11	290 0.7×	314 1.1×	96 0.5×	41 0.3×	14 0.2×	37	492
Naomi Jiang United States	7	219 0.6×	158 0.6×	193 1.0×	94 0.8×	20 0.3×	11	560
Takeshi Ebara Japan	16	364 0.9×	162 0.6×	108 0.6×	49 0.4×	23 0.3×	47	584
Hui Chang China	15	158 0.4×	399 1.4×	125 0.6×	125 1.0×	31 0.4×	47	662
P. Dickinson United Kingdom	11	208 0.5×	208 0.7×	100 0.5×	69 0.6×	14 0.2×	22	471
Sonia Yip Australia	14	361 0.9×	308 1.1×	74 0.4×	83 0.7×	13 0.2×	75	662
Maria Carmen De Santis Italy	14	132 0.3×	212 0.8×	129 0.7×	285 2.3×	18 0.3×	63	521

Countries citing papers authored by Pascal Dô

Since Specialization

Citations

This map shows the geographic impact of Pascal Dô's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Dô with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Dô more than expected).

Fields of papers citing papers by Pascal Dô

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Dô. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Dô. The network helps show where Pascal Dô may publish in the future.

Co-authorship network of co-authors of Pascal Dô

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Dô. A scholar is included among the top collaborators of Pascal Dô based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Dô. Pascal Dô is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Descourt, R., M. Pérol, David Planchard, et al.. (2022). Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. Cancers. 14(7). 1751–1751. 5 indexed citations

Auliac, J.B., Pascal Dô, S. Bayle, et al.. (2019). Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14. Advances in Therapy. 36(8). 2161–2166. 11 indexed citations

Descourt, R., M. Pérol, David Planchard, et al.. (2019). Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer. 136. 109–114. 17 indexed citations

Lesueur, Paul, Alexandre Escande, Juliette Thariat, et al.. (2018). Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC. Cancer Medicine. 7(11). 5505–5513. 36 indexed citations

Baut, Guillaume Le, Jean‐Marc Guilloit, Yann Ollivier, et al.. (2018). Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy. Journal of Gastrointestinal Oncology. 9(3). E15–E18. 1 indexed citations

Lasnon, Charline, Idlir Licaj, Pascal Dô, et al.. (2018). Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 46(2). 421–428. 28 indexed citations

Bennouna, Jaafar, Fabrice Barlési, Pascal Dô, et al.. (2018). Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer). ESMO Open. 3(5). e000394–e000394. 1 indexed citations

Cadranel, J., Alexis B. Cortot, H. Léna, et al.. (2018). Real-life experience of ceritinib in crizotinib-pretreatedALK⁺advanced non-small cell lung cancer patients. ERJ Open Research. 4(1). 58–2017. 6 indexed citations

Chouaïd, C., Pascal Dô, Jaafar Bennouna, et al.. (2017). Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers. Journal of Thoracic Oncology. 12(10). 1496–1502. 30 indexed citations

10.

Baldacci, Simon, Julien Mazières, Pascale Tomasini, et al.. (2017). P3.02b-051 Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study. Journal of Thoracic Oncology. 12(1). S1219–S1220.

11.

Paris, Christophe, Pascal Dô, Bénédicte Mastroïanni, et al.. (2017). Association between lung cancer somatic mutations and occupational exposure in never-smokers. European Respiratory Journal. 50(4). 1700716–1700716. 12 indexed citations

12.

Gandhi, Leena, Sai‐Hong Ignatius Ou, Alice T. Shaw, et al.. (2017). Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. European Journal of Cancer. 82. 27–33. 24 indexed citations

13.

Scherpereel, Arnaud, Laurent Greillier, Pascal Dô, et al.. (2017). Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.. Journal of Clinical Oncology. 35(15_suppl). LBA8507–LBA8507. 12 indexed citations

14.

Johnson, Alison, Pascal Dô, Nicolas Richard, et al.. (2016). Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA. Lung Cancer. 99. 38–40. 8 indexed citations

15.

Lasnon, Charline, Cédric Desmonts, Pascal Dô, et al.. (2016). Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction. Annals of Nuclear Medicine. 31(2). 125–134. 34 indexed citations

16.

Lasnon, Charline, Mohamed Majdoub, Pascal Dô, et al.. (2016). 18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 43(13). 2324–2335. 45 indexed citations

17.

Vergnenègre, A., Bartomeu Massutí, Filippo de Marinis, et al.. (2016). Economic Analysis of First-Line Treatment with Erlotinib in an EGFR -Mutated Population with Advanced NSCLC. Journal of Thoracic Oncology. 11(6). 801–807. 13 indexed citations

18.

Chouaïd, C., C. Dujon, Pascal Dô, et al.. (2014). Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 86(2). 170–173. 132 indexed citations

19.

Borget, Isabelle, M. Pérol, David Pérol, et al.. (2014). Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. BMC Cancer. 14(1). 953–953. 8 indexed citations

20.

Lasnon, Charline, Cédric Desmonts, Elske Quak, et al.. (2013). Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 40(7). 985–996. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact